Valley Hospital First to Use Landiolol for Cardiac Arrhythmia

On Apr 2, 2026

The Valley Hospital has become the first hospital in the United States to use Rapiblyk^® (landiolol) to treat cardiac arrhythmias among the critically ill patient population. The cardiac critical care team at The Valley Hospital administered the medication as a treatment for atrial fibrillation with a rapid heart rate.

Landiolol is a fast-acting, intravenous beta blocker indicated for the short-term reduction of ventricular rate (the number of times the heart’s ventricles contract per minute) in adults with supraventricular tachycardia, including atrial fibrillation and atrial flutter as well as pediatric patients with supraventricular tachycardia – according to manufacturer AOP Orphan Pharmaceuticals GmbH (AOP Health US). The medication is administered intravenously – via an IV line – in the inpatient hospital setting, often in critical care situations.

The medication had been approved for use in Europe, Japan, and Canada, and was FDA-approved for use in the United States in November 2024.

“We are excited to be at the forefront of caring for critically ill patients with cardiac arrhythmia by making new treatment options available to our patients at The Valley Hospital,” said Yonathan Litwok, MD, director of cardiac critical care at The Valley Hospital. “Valley’s cardiac critical care team stays up to date with the latest innovations and treatments in our field, to provide our patients with high-quality care.”

“I am proud of the continued innovation displayed by our team at The Valley Hospital,” said Suneet Mittal, MD, Chair of the Cardiovascular Service Line for Valley Health System. “We will continue to seek new treatments and therapies to advance the high-quality care we are able to offer our patients.”

To access more business news, visit NJB News Now.

Related Articles: